These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33910760)

  • 21. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
    Willemse JL; Hendriks DF
    Clin Chem; 2006 Jan; 52(1):30-6. PubMed ID: 16299049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteolytic activation of purified human procarboxypeptidase U.
    Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
    Clin Chim Acta; 2000 Feb; 292(1-2):25-40. PubMed ID: 10686274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A role for procarboxypepidase U (TAFI) in thrombosis.
    Willemse JL; Hendriks DF
    Front Biosci; 2007 Jan; 12():1973-87. PubMed ID: 17127436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.
    Matus V; Willemse J; Quiroga T; Goycoolea M; Aranda E; Panes O; Pereira J; Hendriks D; Mezzano D
    Clin Chim Acta; 2009 Mar; 401(1-2):158-61. PubMed ID: 19038242
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carboxypeptidase U at the interface between coagulation and fibrinolysis.
    Schatteman K; Goossens F; Leurs J; Verkerk R; Scharpé S; Michiels JJ; Hendriks D
    Clin Appl Thromb Hemost; 2001 Apr; 7(2):93-101. PubMed ID: 11292199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.
    Kim PY; Kim PY; Taylor FB; Nesheim ME
    J Thromb Thrombolysis; 2012 May; 33(4):412-5. PubMed ID: 22228479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.
    Schol-Gelok S; de Maat MPM; Biedermann JS; van Gelder T; Leebeek FWG; Lijfering WM; van der Meer FJM; Rijken DC; Versmissen J; Kruip MJHA
    Br J Haematol; 2020 Sep; 190(6):916-922. PubMed ID: 32301122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
    Brouns R; Heylen E; Willemse JL; Sheorajpanday R; De Surgeloose D; Verkerk R; De Deyn PP; Hendriks DF
    J Thromb Haemost; 2010 Jan; 8(1):75-80. PubMed ID: 19874466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
    Post MS; Hendriks DF; Van Der Mooren MJ; Van Baal WM; Leurs JR; Emeis JJ; Kenemans P; Stehouwer CD
    J Intern Med; 2002 Mar; 251(3):245-51. PubMed ID: 11886484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
    Willemse JL; Heylen E; Nesheim ME; Hendriks DF
    J Thromb Haemost; 2009 Dec; 7(12):1962-71. PubMed ID: 19719827
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thrombin activatable fibrinolysis inhibitor.
    Declerck PJ
    Hamostaseologie; 2011 Aug; 31(3):165-6, 168-73. PubMed ID: 21629966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
    Heylen E; Miljic P; Willemse J; Djordjevic V; Radojkovic D; Colovic M; Elezovic I; Hendriks D
    Thromb Res; 2009 Sep; 124(4):427-32. PubMed ID: 19195685
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
    Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
    Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
    Walker JB; Bajzar L
    J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay.
    Heylen E; Van Goethem S; Augustyns K; Hendriks D
    Anal Biochem; 2010 Aug; 403(1-2):114-6. PubMed ID: 20371219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.
    Leurs J; Nerme V; Sim Y; Hendriks D
    J Thromb Haemost; 2004 Mar; 2(3):416-23. PubMed ID: 15009457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
    Seljeflot I; Tonstad S; Hjermann I; Arnesen H
    Thromb Res; 2002 Feb; 105(4):285-90. PubMed ID: 12031821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.